Andrew Azman, PhD
Image credit: Johns Hopkins Bloomberg School of Public Health
During a hepatitis E outbreak in 2022 in South Sudan at the Bentiu refugee camp, the Hecolin HEV vaccine was shown to be highly protective. The results were published in The Lancet Infectious Diseases.
“In the primary analysis we estimated an unadjusted two-dose vaccine effectiveness of 67.8% (95% CI –28.6 to 91.9), and a 2-dose vaccine effectiveness of 84.0% (–2085 to 992) after adjustment for potential confounders,” the investigators wrote. “The bias indicator analysis suggested that test-negative cases might have been more likely to have been vaccinated than their matched community controls due to different health care seeking behaviors, potentially meaning underestimation of effectiveness estimates. The test-negative design,…